28-day Repeat Dose Study of GSK573719
NCT01030965
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
285
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG:
GSK573719 125mcg
DRUG:
GSK573719 250mcg
DRUG:
GSK573719 500mcg
DRUG:
Placebo
Sponsor
GlaxoSmithKline